Revenue
No reported data
MIRA PHARMACEUTICALS, INC. (MIRA)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $1.7M | $3.3M | $1.6M | $2.4M |
| Operating expenses | $10.5M | $8.0M | $8.5M | $7.0M |
| Net income | −$10.4M | −$7.9M | −$12.0M | −$7.1M |
| Basic EPSper diluted share | -$1.35 | -$0.51 | -$0.85 | -$0.40 |
| Diluted EPSper diluted share | -$1.35 | -$0.51 | -$0.85 | -$0.40 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 16, 2025Form 5 | Aminov ErezCEO and Chairman | SellCommon Stock | 613.6K | $2.11 | $1.29M | 3.59M |
| Nov 20, 2024Form 4 · 10b5-1 | Aminov ErezChief Executive Officer | SellCommon Stock | 44.6K | $1.27 | $56.6K | 1.06M |
| Nov 19, 2024Form 4 · 10b5-1 | Aminov ErezChief Executive Officer | SellCommon Stock | 55.4K | $1.39 | $77.0K | 1.11M |
| Aug 28, 2024Form 4 | McNulty Brian Patrick +1TenPercentOwner | SellCommon Stock · indirect | 200.0K | $1.96 | $392.0K | 2.54M |